Generic Name and Formulations:
Dipivefrin HCl 0.1%; oph. soln; contains benzalkonium chloride.
Indications for PROPINE:
Initial therapy for the control of intraocular pressure in chronic open-angle glaucoma.
1 drop every 12 hrs. Transferring from antiglaucoma agents other than epinephrine: on the first day continue previous medication and add 1 drop of Propine in each eye every 12 hours; on the following day, discontinue previous antiglaucoma agent. Transferring from conventional epinephrine therapy: discontinue epinephrine medication and institute Propine regimen. If additional therapy is required, add 1 drop of Propine every 12 hours to other antiglaucoma agents. Concomitant therapy: may add Propine to pilocarpine, carbachol, echothiophate iodide or acetazolamide for difficult to control patients.
Aphakic patients are at increased risk of developing maculopathy; monitor visual acuity closely. Cardiovascular disease. Hypertension. Pregnancy (Cat.B). Nursing mothers.
Local effects (eg, injection, burning, stinging, follicular conjunctivitis, pain, mydriasis, blurry vision, pruritus, adrenochrome deposits in the conjunctiva and cornea), headache, allergic reaction, cardiovascular effects (eg, tachycardia, arrhythmias, hypertension).
Soln—5mL, 10mL, 15mL